Gilead's M&A streak carries on with buyout of private PARP1, autoimmune biotech

09 May 2023

Gilead’s dealmaking spree, part of biopharma’s “ blistering ” M&A this year, continued on Tuesday with a consummation of oncology and inflammation startup XinThera. After deals for UK startup MiroBio, a Jounce antibody and Tmunity — while passing on Pionyr — Gilead is now further expanding beyond its HIV products with a biotech nearing the clinic with two oral small molecule PARP1 inhibitors PARP1 inhibitors for various tumors. Part of the DNA-repairing enzyme family, PARP is targeted by the likes of AstraZeneca’s Lynparza and GSK and Tesaro’s Zejula, but dose-limiting toxicities limit their use. Merck KGaA , Duke Street Bio and others are interested in next-gen moves.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Gilead Sciences, Inc.

MiroBio Ltd.

Pionyr Immunotherapeutics, Inc.

[+4]

Indications

NeoplasmsInflammation

Targets

PARP1PARP

Drugs

OlaparibSimmiparibNiraparib Tosylate

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.